[1] Abed, Y., Baz, M., and Boivin, G. (2006). Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds.
Antivir Ther 11, 971-976 .
[2] Barrett, S., Mohr, P.G., Schmidt, P.M., and McKimm-Breschkin, J.L. (2011). Real time enzyme inhibition assays provide insights into differences in binding of neuraminidase inhibitors to wild type and mutant influenza viruses.
PLoS One 6, e23627.
10.1371/journal.pone.0023627[3] Ba vagnoli, L., and Maga, G. (2011). The 2009 influenza pandemic: promising lessons for antiviral therapy for future outbreaks.
Current Med Chem 18, 5466-5475 .
10.2174/092986711798194397[4] Bloom, J.D., Gong, L.I., and Baltimore, D. (2010). Permissive secondary mutations enable the evolution of influenza oseltamivir resistance.
Science 328, 1272-1275 .
10.1126/science.1187816[5] Boivin, G., Pizzorno, A., Bouhy, X., and Abed, Y. (2011). Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors.
J Infect Dis 203, 25-31 .
10.1093/infdis/jiq010[6] Boltz, D.A., Douangngeun, B., Phommachanh, P., Sinthasak, S., Mondry, R., Obert, C., Seiler, P., Keating, R., Suzuki, Y., Hiramatsu, H.,
. (2010). Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic Republic.
J Gen Virol 91, 949-959 .
10.1099/vir.0.017459-0[7] Deng, Y.M., Caldwell, N., Hurt, A., Shaw, T., Kelso, A., Chidlow, G., Williams, S., Smith, D., and Barr, I. (2011). A comparison of pyrosequencing and neuraminidase inhibition assays for the detection of oseltamivir-resistant pandemic influenza A(H1N1) 2009 viruses.
Antiviral Res 90, 87-91 .
10.1016/j.antiviral.2011.02.014[8] Earhart, K.C., Elsayed, N.M., Saad, M.D., Gubareva, L.V., Nayel, A., Deyde, V.M., Abdelsattar, A., Abdelghani, A.S., Boynton, B.R., Mansour, M.M.,
. (2009). Oseltamivir resistance mutation N294S in human influenza A(H5N1) virus in Egypt.
J Infect Public Health 2, 74-80 .
10.1016/j.jiph.2009.04.004[9] Eshaghi, A., Patel, S.N., Sarabia, A., Higgins, R.R., Savchenko, A., Stojios, P.J., Li, Y., Bastien, N., Alexander, D.C., Low, D.E.,
. (2011). Multidrug-resistant pandemic (H1N1) 2009 infection in immunocompetent child.
Emerg Infect Dis 17, 1472-1474 .
[10] Ferraris, O., and Lina, B. (2008). Mutations of neuraminidase implicated in neuraminidase inhibitors resistance.
J Clin Virol 41, 13-19 .
10.1016/j.jcv.2007.10.020[11] Garcia, J.M., and Lai, J.C. (2011). Production of influenza pseudotyped lentiviral particles and their use in influenza research and diagnosis: an update.
Expert Rev Anti Infect Ther 9, 443-455 .
10.1586/eri.11.25[12] Gubareva, L.V., Trujillo, A.A., Okomo-Adhiambo, M., Mishin, V.P., Deyde, V.M., Sleeman, K., Nguyen, H.T., Sheu, T.G., Garten, R.J., Shaw, M.W.,
. (2010). Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
Antivir Ther 15, 1151-1159 .
10.3851/IMP1678[13] Hayden, F.G. (2006). Antiviral resistance in influenza viruses—implications for management and pandemic response.
N Engl J Med 354, 785-788 .
10.1056/NEJMp068030[14] Herfst, S., Schrauwen, E.J.A., Linster, M., Chutinimitkul, S., de Wit, E., Munster, V.J., Sorrell, E.M., Bestebroer, T.M., Burke, D.F., Smith, D.J.,
. (2012). Airborne Transmission of Influenza A/H5N1 Virus Between Ferrets.
Science 336, 1534-1541 .
10.1126/science.1213362[15] Hurt, A.C., Holien, J.K., and Barr, I.G. (2009). In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
Antimicrob Agents Chemother 53, 4433-4440 .
10.1128/AAC.00334-09[16] Hurt, A.C., Lee, R.T., Leang, S.K., Cui, L., Deng, Y.M., Phuah, S.P., Caldwell, N., Freeman, K., Komadina, N., Smith, D.,
. (2011). Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation.
Euro Surveill 16.
[17] Ilyushina, N.A., Seiler, J.P., Rehg, J.E., Webster, R.G., Govorkova, E.A., and Fouchier, R.A.M. (2010). Effect of neuraminidase inhibitor- resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets.
PLoS Pathogens 6, e1000933.
10.1371/journal.ppat.1000933[18] Imai, M., Watanabe, T., Hatta, M., Das, S.C., Ozawa, M., Shinya, K., Zhong, G., Hanson, A., Katsura, H., Watanabe, S.,
. (2012). Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets.
Nature 486, 420-428 .
[19] Kuroda, H., Kutner, R.H., Bazan, N.G., and Reiser, J. (2009). Simpli- fi ed lentivirus vector production in protein-free media using polyethylenimine- mediated transfection.
J Virol Methods 157, 113-121 .
10.1016/j.jviromet.2008.11.021[20] Le, M.T., Wertheim, H.F., Nguyen, H.D., Taylor, W., Hoang, P.V., Vuong, C.D., Nguyen, H.L., Nguyen, H.H., Nguyen, T.Q., Nguyen, T.V.,
. (2008). Influenza A H5N1 clade 2.3.4 virus with a different antiviral susceptibility profi le replaced clade 1 virus in humans in northern Vietnam.
PLoS One 3, e3339.
10.1371/journal.pone.0003339[21] Le, Q.M., Kiso, M., Someya, K., Sakai, Y.T., Nguyen, T.H., Nguyen, K.H., Pham, N.D., Ngyen, H.H., Yamada, S., Muramoto, Y.,
. (2005
). Avian flu: isolation of drug-resistant H5N1 virus. Nature 437, 1108.
10.1038/4371108a[22] Legoff, J., Rousset, D., Abou-Jaoude, G., Scemla, A., Ribaud, P., Mercier-Delarue, S., Caro, V., Enouf, V., Simon, F., Molina, J.M.,
. (2012). I223R mutation in influenza A(H1N1)pdm09 neuraminidase confers reduced susceptibility to oseltamivir and zanamivir and enhanced resistance with H275Y.
PLoS One 7, e37095.
10.1371/journal.pone.0037095[23] Mc Kimm-Breschkin, J.L., Selleck, P.W., Usman, T.B., and Johnson, M.A. (2007). Reduced sensitivity of influenza A (H5N1) to oseltamivir.
Emerg Infect Dis 13, 1354-1357 .
10.3201/eid1309.07-0164[24] Monto, A.S. (2003). The role of antivirals in the control of influenza.
Vaccine 21, 1796-1800 .
10.1016/S0264-410X(03)00075-6[25] Nguyen, H.T., Fry, A.M., and Gubareva, L.V. (2012). Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods.
Antivir Ther 17, 159-173 .
10.3851/IMP2067[26] Nguyen, H.T., Fry, A.M., Loveless, P.A., Klimov, A.I., and Gubareva, L.V. (2010). Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir.
Clin Infect Dis 51, 983-984 .
10.1086/656439[27] Nguyen, H.T., Sheu, T.G., Mishin, V.P., Klimov, A.I., and Gubareva, L.V. (2010b). Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
Antimicrob Agents Chemother 54, 3671-3677 .
10.1128/AAC.00581-10[28] Peiris, J.S.M., de Jong, M.D., and Guan, Y. (2007). Avian influenza virus (H5N1): a threat to human health.
Clin Microbiol Rev 20, 243-267 .
10.1128/CMR.00037-06[29] Perez, D.R. (2012). Public health and biosecurity. H5N1 debates: hung up on the wrong questions.
Science 335, 799-801 .
10.1126/science.1219066[30] Potier, M., Mameli, L., Belisle, M., Dallaire, L., and Melancon, S.B. (1979). Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate.
Anal Biochem 94, 287-296 .
10.1016/0003-2697(79)90362-2[31] Schmidt, P.M., Attwood, R.M., Mohr, P.G., Barrett, S.A., and McKimm-Breschkin, J.L. (2011). A generic system for the expression and purify cation of soluble and stable influenza neuraminidase.
PLoS One 6, e16284.
10.1371/journal.pone.0016284[32] Sheu, T.G., Deyde, V.M., Okomo-Adhiambo, M., Garten, R.J., Xu, X., Bright, R.A., Butler, E.N., Wallis, T.R., Klimov, A.I., and Gubareva, L.V. (2008). Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.
Antimicrob Agents Chemother 52, 3284-3292 .
10.1128/AAC.00555-08[33] Su, C.Y., Wang, S.Y., Shie, J.J., Jeng, K.S., Temperton, N.J., Fang, J.M., Wong, C.H., and Cheng, Y.S.E. (2008). In vitro evaluation of neuraminidase inhibitors using the neuraminidase-dependent release assay of hemagglutinin-pseudotyped viruses.
Antiviral Res 79, 199-205 .
10.1016/j.antiviral.2008.03.002[34] Tisoncik, J.R., Guo, Y., Cordero, K., Yu, J., Wang, J., Cao, Y., and Rong, L. (2011). Identifi cation of critical residues of influenza neuraminidase in viral particle release.
Virol J 8, 14.
10.1186/1743-422X-8-14[35] van der Vries, E., Stelma, F.F., and Boucher, C.A. (2010). Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus.
N Engl J Med 363, 1381-1382 .
10.1056/NEJMc1003749[36] van der Vries, E., Veldhuis Kroeze, E.J., Stittelaar, K.J., Linster, M., Van der Linden, A., Schrauwen, E.J., Leijten, L.M., van Amerongen, G., Schutten, M., Kuiken, T.,
. (2011). Multidrug resistant 2009 A/H1N1 influenza clinical isolate with a neuraminidase I223R mutation retains its virulence and transmissibility in ferrets.
PLoS Pathog 7, e1002276.
10.1371/journal.ppat.1002276[37] Wa gner, R., Matrosovich, M., and Klenk, H.D. (2002). Functional balance between haemagglutinin and neuraminidase in influenza virus infections.
Rev Med Virol 12, 159-166 .
10.1002/rmv.352[38]
WH O Cumulative number of confi rmed human cases of avian infl uenza A(H5N1) reported to WHO,
http://www.who.int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/index.html.[39] Xu, X., Subbarao, Cox, N.J., and Guo, Y. (1999). Genetic characterization of the pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong.
Virology 261, 15-19 .
10.1006/viro.1999.9820[40] Yen, H.L., Hoffmann, E., Taylor, G., Scholtissek, C., Monto, A.S., Webster, R.G., and Govorkova, E.A. (2006). Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses.
J Virol 80, 8787-8795 .
10.1128/JVI.00477-06[41] Yen, H.L., Ilyushina, N.A., Salomon, R., Hoffmann, E., Webster, R.G., and Govorkova, E.A. (2007). Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication effi ciency and pathogenicity in vitro and in vivo.
J Virol 81, 12418-12426 .
10.1128/JVI.01067-07[42] Zhang, Y.H., Lin, X.J., Wang, G.Q., Zhou, J.F., Lu, J., Zhao, H.L., Zhang, F.W., Wu, J., Xu, C.Q., Du, N.,
. (2010). Neuraminidase and hemagglutinin matching patterns of a highly pathogenic avian and two pandemic H1N1 influenza A viruses.
PLoS One 5, e9167.
10.1371/journal.pone.0009167